Literature DB >> 23445738

Long-term management of Kawasaki disease: implications for the adult patient.

Cedric Manlhiot1, Elizabeth Niedra, Brian W McCrindle.   

Abstract

Coronary artery complications from Kawasaki disease (KD) range from no involvement to giant coronary artery aneurysms (CAA). Current long-term management protocols are calibrated to the degree of maximal and current coronary artery involvement reflecting the known likelihood of severe long-term cardiac complications. It has recently been suggested that all KD patients may be at potential risk of severe long-term cardiac complications. If this assertion was to be confirmed, current follow-up protocols would need to be extensively modified, with important implications both for the growing adult population with a previous history of KD and for the healthcare system. Based on the available evidence, patients with multiple large and/or giant CAA are at substantial risk of severe long-term cardiac complications and should have regular specialized follow-up. Patients with transient or no CAA have not been reported to be at risk of severe long-term cardiac complications. The influence of KD on the atherosclerotic process remains suboptimally defined, and should be the focus of future studies. Heightened cardiovascular risk factor surveillance and management is recommended regardless of coronary artery involvement. Based on the currently available evidence, existing long-term management protocols seem to be appropriately calibrated to the level of risk. Revised long-term management protocols should incorporate newer, noninvasive imaging methods and intensive management of atherosclerotic risk. There is insufficient evidence at this time to mandate long-term specialized follow-up and invasive testing for patients who have not had CAA.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2013        PMID: 23445738     DOI: 10.1016/j.pedneo.2012.12.013

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  7 in total

1.  Myocardial fibrosis after adrenergic stimulation as a long-term sequela in a mouse model of Kawasaki disease vasculitis.

Authors:  Harry H Matundan; Jon Sin; Magali Noval Rivas; Michael C Fishbein; Thomas J Lehman; Shuang Chen; Roberta A Gottlieb; Timothy R Crother; Masanori Abe; Moshe Arditi
Journal:  JCI Insight       Date:  2019-02-07

2.  Cardiovascular Outcomes During Index Hospitalization in Children with Kawasaki Disease in Ontario, Canada.

Authors:  Cal Robinson; Megan Schlorff; Rahul Chanchlani; Anastasia Gayowsky; Elizabeth Darling; Tapas Mondal; Hsien Seow; Michelle Batthish
Journal:  Pediatr Cardiol       Date:  2022-09-08       Impact factor: 1.838

3.  Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.

Authors:  Elizabeth Niedra; Nita Chahal; Cedric Manlhiot; Rae S M Yeung; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2013-07-18       Impact factor: 1.655

4.  Coronary artery stenosis risk and time course in Kawasaki disease patients: experience at a US tertiary pediatric centre.

Authors:  Alok Sunil Patel; Margaret Bruce; Whitney Harrington; Michael A Portman
Journal:  Open Heart       Date:  2015-03-17

5.  A Combination Therapy for Kawasaki Disease with Severe Complications: a Case Report.

Authors:  Yuriko Abe; Mamoru Ayusawa; Kengo Kawamura; Ryuta Yonezawa; Masataka Kato; Akiko Komori; Ryutaro Kohira; Ichiro Morioka
Journal:  Open Med (Wars)       Date:  2019-12-26

6.  COVID-19-Associated Multisystem Inflammatory Syndrome Complicated with Giant Coronary Artery Aneurysm.

Authors:  Mohammad Reza Navaeifar; Leila Shahbaznejad; Ali Sadeghi Lotfabadi; Mohammad Sadegh Rezai
Journal:  Case Rep Pediatr       Date:  2021-01-06

Review 7.  Kawasaki disease: pathophysiology, clinical manifestations, and management.

Authors:  Victoria R Dimitriades; Amanda G Brown; Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.